Macular degeneration and diabetic retinopathy are reaching epidemic portions and the way that your Retina Specialist treats may change.-MDA
ATLAS study: Treat-and-extend with aflibercept reduces AMD treatment burden
SAN FRANCISCO — Treat-and-extend aflibercept therapy for neovascular age-related macular degeneration improved vision and significantly reduced the treatment burden at 2 years, according to a scientific poster presented here at the American Society of Retina Specialists meeting.
“A treat-and-extend injection protocol using aflibercept for neovascular age-related macular degeneration allowed more than a third of patients to achieve an injection interval of 12 weeks or longer,” lead author David C. Reed, MD,wrote.
The prospective, multicenter, open-label ATLAS study included 40 eyes of 40 patients treated every 4 weeks with Eylea (aflibercept, Regeneron) until no signs of macular exudation were visible.
The treatment intervals were extended by 2 weeks until an exudative recurrence occurred or a treatment interval of 16 weeks was attained.
An average of eight treatments improved best corrected visual acuity by a median of 11 letters and decreased central retinal thickness by 163 µm in year 1…..
Read more: http://www.healio.com/ophthalmology/retina-vitreous/news/online/%7B85299509-224b-4810-b347-a91b141186e4%7D/atlas-study-treat-and-extend-with-aflibercept-reduces-amd-treatment-burden